ID   DPOG1_HUMAN             Reviewed;        1239 AA.
AC   P54098; Q8NFM2; Q92515;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-APR-2017, entry version 186.
DE   RecName: Full=DNA polymerase subunit gamma-1;
DE            EC=2.7.7.7;
DE   AltName: Full=Mitochondrial DNA polymerase catalytic subunit;
DE   AltName: Full=PolG-alpha;
GN   Name=POLG; Synonyms=MDP1, POLG1, POLGA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8884268; DOI=10.1006/geno.1996.0490;
RA   Ropp P.A., Copeland W.C.;
RT   "Cloning and characterization of the human mitochondrial DNA
RT   polymerase, DNA polymerase gamma.";
RL   Genomics 36:449-458(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9034326; DOI=10.1016/S0378-1119(96)00663-4;
RA   Lecrenier N.L., van der Bruggen P., Foury F.;
RT   "Mitochondrial DNA polymerases from yeast to man: a new family of
RT   polymerases.";
RL   Gene 185:147-152(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLN-GLN-55 INS.
RC   TISSUE=Brain;
RA   Watanabe T.K., Shimizu F., Nishino N., Fujiwara T., Kanemoto N.,
RA   Suzuki M., Nakamura Y., Hirai Y., Maekawa H., Takahashi E.;
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-55 INS; GLN-193;
RP   CYS-546; LYS-662; TRP-1142; GLY-1143; CYS-1146 AND HIS-1236.
RG   NIEHS SNPs program;
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBCELLULAR LOCATION, ASSOCIATION WITH MITOCHONDRIAL DNA, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18063578; DOI=10.1074/jbc.M708444200;
RA   Bogenhagen D.F., Rousseau D., Burke S.;
RT   "The layered structure of human mitochondrial DNA nucleoids.";
RL   J. Biol. Chem. 283:3665-3675(2008).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [8]
RP   INVOLVEMENT IN SCAE, AND VARIANTS SCAE THR-467; HIS-497 AND SER-748.
RX   PubMed=26942291; DOI=10.1016/j.ajhg.2016.01.009;
RA   Sandford E., Bird T.D., Li J.Z., Burmeister M.;
RT   "PRICKLE2 mutations might not be involved in epilepsy.";
RL   Am. J. Hum. Genet. 98:588-589(2016).
RN   [9]
RP   VARIANTS PEOB1 PRO-3; ARG-304; THR-467 AND CYS-955.
RX   PubMed=11431686; DOI=10.1038/90034;
RA   Van Goethem G., Dermaut B., Loefgren A., Martin J.-J.,
RA   Van Broeckhoven C.;
RT   "Mutation of POLG is associated with progressive external
RT   ophthalmoplegia characterized by mtDNA deletions.";
RL   Nat. Genet. 28:211-212(2001).
RN   [10]
RP   VARIANTS PEOA1 ASP-923; HIS-943; CYS-955; SER-957 AND LEU-1176, AND
RP   VARIANTS PEO ILE-251; LEU-309 AND SER-848.
RX   PubMed=12210792; DOI=10.1002/ana.10278;
RA   Lamantea E., Tiranti V., Bordoni A., Toscano A., Bono F., Servidei S.,
RA   Papadimitriou A., Spelbrink H., Silvestri L., Casari G., Comi G.P.,
RA   Zeviani M.;
RT   "Mutations of mitochondrial DNA polymerase gammaA are a frequent cause
RT   of autosomal dominant or recessive progressive external
RT   ophthalmoplegia.";
RL   Ann. Neurol. 52:211-219(2002).
RN   [11]
RP   CHARACTERIZATION OF VARIANT PEOA1 CYS-955.
RX   PubMed=11897778; DOI=10.1074/jbc.C200100200;
RA   Ponamarev M.V., Longley M.J., Nguyen D., Kunkel T.A., Copeland W.C.;
RT   "Active site mutation in DNA polymerase gamma associated with
RT   progressive external ophthalmoplegia causes error-prone DNA
RT   synthesis.";
RL   J. Biol. Chem. 277:15225-15228(2002).
RN   [12]
RP   VARIANTS PEOB1 TRP-579; LEU-587; THR-889 AND VAL-1076, AND VARIANT
RP   HIS-1236.
RX   PubMed=12975295; DOI=10.1001/archneur.60.9.1279;
RA   Filosto M., Mancuso M., Nishigaki Y., Pancrudo J., Harati Y.,
RA   Gooch C., Mankodi A., Bayne L., Bonilla E., Shanske S., Hirano M.,
RA   DiMauro S.;
RT   "Clinical and genetic heterogeneity in progressive external
RT   ophthalmoplegia due to mutations in polymerase gamma.";
RL   Arch. Neurol. 60:1279-1284(2003).
RN   [13]
RP   VARIANTS MTDPS4B ILE-251; LEU-587 AND SER-864.
RX   PubMed=12825077; DOI=10.1038/sj.ejhg.5201002;
RA   Van Goethem G., Schwartz M., Loefgren A., Dermaut B.,
RA   Van Broeckhoven C., Vissing J.;
RT   "Novel POLG mutations in progressive external ophthalmoplegia
RT   mimicking mitochondrial neurogastrointestinal encephalomyopathy.";
RL   Eur. J. Hum. Genet. 11:547-549(2003).
RN   [14]
RP   VARIANT PEOB1 SER-848.
RX   PubMed=12872260; DOI=10.1002/humu.10246;
RA   Van Goethem G., Loefgren A., Dermaut B., Ceuterick C., Martin J.-J.,
RA   Van Broeckhoven C.;
RT   "Digenic progressive external ophthalmoplegia in a sporadic patient:
RT   recessive mutations in POLG and C10orf2/Twinkle.";
RL   Hum. Mutat. 22:175-176(2003).
RN   [15]
RP   VARIANTS PEOB1 ILE-251; ALA-268; ARG-312; THR-467; GLN-562; LEU-587;
RP   PRO-807 AND TYR-932, AND VARIANTS GLY-1143 AND HIS-1236.
RX   PubMed=14635118; DOI=10.1002/humu.9203;
RA   Di Fonzo A., Bordoni A., Crimi M., Sara G., Del Bo R., Bresolin N.,
RA   Comi G.P.;
RT   "POLG mutations in sporadic mitochondrial disorders with multiple
RT   mtDNA deletions.";
RL   Hum. Mutat. 22:498-499(2003).
RN   [16]
RP   VARIANTS PEOB1 TRP-227; ILE-251; ARG-312; VAL-431; THR-467; GLN-1047;
RP   CYS-1096 AND CYS-1104.
RX   PubMed=12707443; DOI=10.1212/01.WNL.0000056088.09408.3C;
RA   Agostino A., Valletta L., Chinnery P.F., Ferrari G., Carrara F.,
RA   Taylor R.W., Schaefer A.M., Turnbull D.M., Tiranti V., Zeviani M.;
RT   "Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive
RT   external ophthalmoplegia (PEO).";
RL   Neurology 60:1354-1356(2003).
RN   [17]
RP   VARIANT MERRF THR-467.
RX   PubMed=14694057; DOI=10.1212/01.WNL.0000098997.23471.65;
RA   Van Goethem G., Mercelis R., Loefgren A., Seneca S., Ceuterick C.,
RA   Martin J.-J., Van Broeckhoven C.;
RT   "Patient homozygous for a recessive POLG mutation presents with
RT   features of MERRF.";
RL   Neurology 61:1811-1813(2003).
RN   [18]
RP   VARIANTS PEOB1 PRO-3; ARG-304; THR-467 AND CYS-955, AND VARIANT SANDO
RP   TRP-627.
RX   PubMed=12565911; DOI=10.1016/S0960-8966(02)00216-X;
RA   Van Goethem G., Martin J.-J., Dermaut B., Loefgren A., Wibail A.,
RA   Ververken D., Tack P., Dehaene I., Van Zandijcke M., Moonen M.,
RA   Ceuterick C., De Jonghe P., Van Broeckhoven C.;
RT   "Recessive POLG mutations presenting with sensory and ataxic
RT   neuropathy in compound heterozygote patients with progressive external
RT   ophthalmoplegia.";
RL   Neuromuscul. Disord. 13:133-142(2003).
RN   [19]
RP   VARIANT MTDPS4A THR-467.
RX   PubMed=15122711; DOI=10.1002/ana.20079;
RA   Naviaux R.K., Nguyen K.V.;
RT   "POLG mutations associated with Alpers' syndrome and mitochondrial DNA
RT   depletion.";
RL   Ann. Neurol. 55:706-712(2004).
RN   [20]
RP   VARIANTS PEOB1 TRP-227; ILE-251 LEU-309; LEU-587; SER-848 ILE-1106 AND
RP   LEU-1176.
RX   PubMed=15349879; DOI=10.1002/ana.20219;
RA   Lamantea E., Zeviani M.;
RT   "Sequence analysis of familial PEO shows additional mutations
RT   associated with the 752C-->T and 3527C-->T changes in the POLG1
RT   gene.";
RL   Ann. Neurol. 56:454-455(2004).
RN   [21]
RP   VARIANT PEOA1 CYS-831.
RX   PubMed=15534189; DOI=10.1001/archneur.61.11.1777;
RA   Mancuso M., Filosto M., Oh S.J., DiMauro S.;
RT   "A novel polymerase gamma mutation in a family with ophthalmoplegia,
RT   neuropathy, and parkinsonism.";
RL   Arch. Neurol. 61:1777-1779(2004).
RN   [22]
RP   VARIANTS PEOA1 CYS-953 AND CYS-955, AND VARIANTS PEOB1 ASP-468 AND
RP   THR-1105.
RX   PubMed=15351195; DOI=10.1016/S0140-6736(04)16983-3;
RA   Luoma P., Melberg A., Rinne J.O., Kaukonen J.A., Nupponen N.N.,
RA   Chalmers R.M., Oldfors A., Rautakorpi I., Peltonen L., Majamaa K.,
RA   Somer H., Suomalainen A.;
RT   "Parkinsonism, premature menopause, and mitochondrial DNA polymerase
RT   gamma mutations: clinical and molecular genetic study.";
RL   Lancet 364:875-882(2004).
RN   [23]
RP   VARIANTS SANDO TYR-932 AND ARG-1051.
RX   PubMed=14745080; DOI=10.1212/WNL.62.2.316;
RA   Mancuso M., Filosto M., Bellan M., Liguori R., Montagna P.,
RA   Baruzzi A., DiMauro S., Carelli V.;
RT   "POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy,
RT   ataxia, and deafness.";
RL   Neurology 62:316-318(2004).
RN   [24]
RP   VARIANT PEOB1 THR-467, VARIANT SANDO SER-748, AND VARIANT GLY-1143.
RX   PubMed=15477547; DOI=10.1212/01.WNL.0000140494.58732.83;
RA   Van Goethem G., Luoma P., Rantamaeki M., Al-Memar A., Kaakkola S.,
RA   Hackman P., Krahe R., Loefgren A., Martin J.-J., De Jonghe P.,
RA   Suomalainen A., Udd B., Van Broeckhoven C.;
RT   "POLG mutations in neurodegenerative disorders with ataxia but no
RT   muscle involvement.";
RL   Neurology 63:1251-1257(2004).
RN   [25]
RP   VARIANT SANDO SER-748, AND VARIANT GLY-1143.
RX   PubMed=16080118; DOI=10.1086/444548;
RA   Hakonen A.H., Heiskanen S., Juvonen V., Lappalainen I., Luoma P.T.,
RA   Rantamaeki M., Van Goethem G., Loefgren A., Hackman P., Paetau A.,
RA   Kaakkola S., Majamaa K., Varilo T., Udd B., Kaeaeriaeinen H.,
RA   Bindoff L.A., Suomalainen A.;
RT   "Mitochondrial DNA polymerase W748S mutation: a common cause of
RT   autosomal recessive ataxia with ancient European origin.";
RL   Am. J. Hum. Genet. 77:430-441(2005).
RN   [26]
RP   VARIANTS MTDPS4A SER-748 AND SER-848.
RX   PubMed=15929042; DOI=10.1002/ana.20498;
RA   Davidzon G., Mancuso M., Ferraris S., Quinzii C., Hirano M.,
RA   Peters H.L., Kirby D., Thorburn D.R., DiMauro S.;
RT   "POLG mutations and Alpers syndrome.";
RL   Ann. Neurol. 57:921-923(2005).
RN   [27]
RP   VARIANTS MTDPS4A GLY-232; PRO-244; ILE-251 THR-467; LEU-587; SER-748
RP   SER-848 AND PRO-957, AND VARIANT GLY-1143.
RX   PubMed=15689359; DOI=10.1093/brain/awh410;
RA   Ferrari G., Lamantea E., Donati A., Filosto M., Briem E., Carrara F.,
RA   Parini R., Simonati A., Santer R., Zeviani M.;
RT   "Infantile hepatocerebral syndromes associated with mutations in the
RT   mitochondrial DNA polymerase-gammaA.";
RL   Brain 128:723-731(2005).
RN   [28]
RP   VARIANT PEOB1 THR-467, VARIANT SANDO GLN-627, VARIANT HIS-1236,
RP   CHARACTERIZATION OF VARIANT PEOB1 THR-467, AND CHARACTERIZATION OF
RP   VARIANT SANDO GLN-627.
RX   PubMed=15917273; DOI=10.1093/hmg/ddi196;
RA   Luoma P.T., Luo N., Loescher W.N., Farr C.L., Horvath R.,
RA   Wanschitz J., Kiechl S., Kaguni L.S., Suomalainen A.;
RT   "Functional defects due to spacer-region mutations of human
RT   mitochondrial DNA polymerase in a family with an ataxia-myopathy
RT   syndrome.";
RL   Hum. Mol. Genet. 14:1907-1920(2005).
RN   [29]
RP   VARIANTS SANDO THR-467; HIS-497 AND SER-748.
RX   PubMed=15824347; DOI=10.1212/01.WNL.0000156516.77696.5A;
RA   Winterthun S., Ferrari G., He L., Taylor R.W., Zeviani M.,
RA   Turnbull D.M., Engelsen B.A., Moen G., Bindoff L.A.;
RT   "Autosomal recessive mitochondrial ataxic syndrome due to
RT   mitochondrial polymerase gamma mutations.";
RL   Neurology 64:1204-1208(2005).
RN   [30]
RP   VARIANTS PEOB1 ARG-737 AND TRP-853.
RX   PubMed=16634032; DOI=10.1002/ana.20831;
RA   Davidzon G., Greene P., Mancuso M., Klos K.J., Ahlskog J.E.,
RA   Hirano M., DiMauro S.;
RT   "Early-onset familial parkinsonism due to POLG mutations.";
RL   Ann. Neurol. 59:859-862(2006).
RN   [31]
RP   VARIANTS PEOB1 LEU-603; TRP-853; CYS-1146 AND ASN-1184.
RX   PubMed=16401742; DOI=10.1001/archneur.63.1.107;
RA   Gonzalez-Vioque E., Blazquez A., Fernandez-Moreira D., Bornstein B.,
RA   Bautista J., Arpa J., Navarro C., Campos Y., Fernandez-Moreno M.A.,
RA   Garesse R., Arenas J., Martin M.A.;
RT   "Association of novel POLG mutations and multiple mitochondrial DNA
RT   deletions with variable clinical phenotypes in a Spanish population.";
RL   Arch. Neurol. 63:107-111(2006).
RN   [32]
RP   VARIANTS PEOB1 HIS-308; TRP-574 AND ARG-648, VARIANT SANDO VAL-517,
RP   AND VARIANTS MTDPS4A ASP-767; HIS-879; SER-885; PRO-914; HIS-1096 AND
RP   ASN-1191.
RX   PubMed=16621917; DOI=10.1093/brain/awl088;
RA   Horvath R., Hudson G., Ferrari G., Fuetterer N., Ahola S.,
RA   Lamantea E., Prokisch H., Lochmueller H., McFarland R., Ramesh V.,
RA   Klopstock T., Freisinger P., Salvi F., Mayr J.A., Santer R.,
RA   Tesarova M., Zeman J., Udd B., Taylor R.W., Turnbull D., Hanna M.,
RA   Fialho D., Suomalainen A., Zeviani M., Chinnery P.F.;
RT   "Phenotypic spectrum associated with mutations of the mitochondrial
RT   polymerase gamma gene.";
RL   Brain 129:1674-1684(2006).
RN   [33]
RP   VARIANTS PEOB1 ARG-304; ASP-380 AND THR-467, VARIANT SANDO SER-748,
RP   VARIANT MTDPS4A PRO-914, AND VARIANTS GLY-1143 AND HIS-1236.
RX   PubMed=16639411; DOI=10.1038/sj.ejhg.5201627;
RA   Naiemi M., Bannwarth S., Procaccio V., Pouget J., Desnuelle C.,
RA   Pellissier J.-F., Roetig A., Munnich A., Calvas P., Richelme C.,
RA   Jonveaux P., Castelnovo G., Simon M., Clanet M., Wallace D.,
RA   Paquis-Flucklinger V.;
RT   "Molecular analysis of ANT1, TWINKLE and POLG in patients with
RT   multiple deletions or depletion of mitochondrial DNA by a dHPLC-based
RT   assay.";
RL   Eur. J. Hum. Genet. 14:917-922(2006).
RN   [34]
RP   ERRATUM.
RA   Naiemi M., Bannwarth S., Procaccio V., Pouget J., Desnuelle C.,
RA   Pellissier J.-F., Roetig A., Munnich A., Calvas P., Richelme C.,
RA   Jonveaux P., Castelnovo G., Simon M., Clanet M., Wallace D.,
RA   Paquis-Flucklinger V.;
RL   Eur. J. Hum. Genet. 15:607-607(2006).
RN   [35]
RP   VARIANTS SANDO ARG-648 AND CYS-807.
RX   PubMed=16919951; DOI=10.1016/j.nmd.2006.05.016;
RA   Gago M.F., Rosas M.J., Guimaraes J., Ferreira M., Vilarinho L.,
RA   Castro L., Carpenter S.;
RT   "SANDO: two novel mutations in POLG1 gene.";
RL   Neuromuscul. Disord. 16:507-509(2006).
RN   [36]
RP   VARIANT PEOA1 ASN-511, AND VARIANT PHE-463.
RX   PubMed=17420318; DOI=10.1001/archneur.64.4.553;
RA   Hudson G., Schaefer A.M., Taylor R.W., Tiangyou W., Gibson A.,
RA   Venables G., Griffiths P., Burn D.J., Turnbull D.M., Chinnery P.F.;
RT   "Mutation of the linker region of the polymerase gamma-1 (POLG1) gene
RT   associated with progressive external ophthalmoplegia and
RT   Parkinsonism.";
RL   Arch. Neurol. 64:553-557(2007).
RN   [37]
RP   VARIANT PEOA1 CYS-831.
RX   PubMed=17846414; DOI=10.1212/01.wnl.0000276955.23735.eb;
RA   Luoma P.T., Eerola J., Ahola S., Hakonen A.H., Hellstroem O.,
RA   Kivistoe K.T., Tienari P.J., Suomalainen A.;
RT   "Mitochondrial DNA polymerase gamma variants in idiopathic sporadic
RT   Parkinson disease.";
RL   Neurology 69:1152-1159(2007).
RN   [38]
RP   VARIANT PEOA1 HIS-1186.
RX   PubMed=18575922; DOI=10.1007/s00415-008-0926-3;
RA   Virgilio R., Ronchi D., Hadjigeorgiou G.M., Bordoni A., Saladino F.,
RA   Moggio M., Adobbati L., Kafetsouli D., Tsironi E., Previtali S.,
RA   Papadimitriou A., Bresolin N., Comi G.P.;
RT   "Novel Twinkle (PEO1) gene mutations in Mendelian progressive external
RT   ophthalmoplegia.";
RL   J. Neurol. 255:1384-1391(2008).
RN   [39]
RP   VARIANTS LS HIS-232 AND SER-848, VARIANTS MTDPS4A ILE-251; THR-467;
RP   LEU-587; SER-748; CYS-831; SER-848; PRO-914; TYR-1110; ARG-1134 AND
RP   LYS-1136, AND VARIANTS GLY-1143 AND HIS-1236.
RX   PubMed=18828154; DOI=10.1002/humu.20852;
RA   Taanman J.-W., Rahman S., Pagnamenta A.T., Morris A.A.M.,
RA   Bitner-Glindzicz M., Wolf N.I., Leonard J.V., Clayton P.T.,
RA   Schapira A.H.V.;
RT   "Analysis of mutant DNA polymerase gamma in patients with
RT   mitochondrial DNA depletion.";
RL   Hum. Mutat. 30:248-254(2009).
RN   [40]
RP   VARIANTS MTDPS4B TRP-227 AND SER-848.
RX   PubMed=19307547; DOI=10.1212/01.wnl.0000345002.47396.e1;
RA   Giordano C., Powell H., Leopizzi M., de Curtis M., Travaglini C.,
RA   Sebastiani M., Gallo P., Taylor R.W., d'Amati G.;
RT   "Fatal congenital myopathy and gastrointestinal pseudo-obstruction due
RT   to POLG1 mutations.";
RL   Neurology 72:1103-1105(2009).
CC   -!- FUNCTION: Involved in the replication of mitochondrial DNA.
CC       Associates with mitochondrial DNA.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1).
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Heterotrimer composed of a catalytic subunit and a
CC       homodimer of accessory subunits.
CC   -!- INTERACTION:
CC       Q9UHN1:POLG2; NbExp=10; IntAct=EBI-852624, EBI-852642;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:18063578}.
CC       Mitochondrion matrix, mitochondrion nucleoid
CC       {ECO:0000269|PubMed:18063578}.
CC   -!- POLYMORPHISM: The poly-Gln region seems to be polymorphic.
CC   -!- DISEASE: Progressive external ophthalmoplegia with mitochondrial
CC       DNA deletions, autosomal dominant, 1 (PEOA1) [MIM:157640]: A
CC       disorder characterized by progressive weakness of ocular muscles
CC       and levator muscle of the upper eyelid. In a minority of cases, it
CC       is associated with skeletal myopathy, which predominantly involves
CC       axial or proximal muscles and which causes abnormal fatigability
CC       and even permanent muscle weakness. Ragged-red fibers and atrophy
CC       are found on muscle biopsy. A large proportion of chronic
CC       ophthalmoplegias are associated with other symptoms, leading to a
CC       multisystemic pattern of this disease. Additional symptoms are
CC       variable, and may include cataracts, hearing loss, sensory axonal
CC       neuropathy, ataxia, depression, hypogonadism, and parkinsonism.
CC       {ECO:0000269|PubMed:11897778, ECO:0000269|PubMed:12210792,
CC       ECO:0000269|PubMed:15351195, ECO:0000269|PubMed:15534189,
CC       ECO:0000269|PubMed:17420318, ECO:0000269|PubMed:17846414,
CC       ECO:0000269|PubMed:18575922}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Progressive external ophthalmoplegia with mitochondrial
CC       DNA deletions, autosomal recessive, 1 (PEOB1) [MIM:258450]: A
CC       severe form of progressive external ophthalmoplegia, a disorder
CC       characterized by progressive weakness of ocular muscles and
CC       levator muscle of the upper eyelid. It is clinically more
CC       heterogeneous than the autosomal dominant forms.
CC       {ECO:0000269|PubMed:11431686, ECO:0000269|PubMed:12565911,
CC       ECO:0000269|PubMed:12707443, ECO:0000269|PubMed:12872260,
CC       ECO:0000269|PubMed:12975295, ECO:0000269|PubMed:14635118,
CC       ECO:0000269|PubMed:15349879, ECO:0000269|PubMed:15351195,
CC       ECO:0000269|PubMed:15477547, ECO:0000269|PubMed:15917273,
CC       ECO:0000269|PubMed:16401742, ECO:0000269|PubMed:16621917,
CC       ECO:0000269|PubMed:16634032, ECO:0000269|PubMed:16639411}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Sensory ataxic neuropathy dysarthria and ophthalmoparesis
CC       (SANDO) [MIM:607459]: A systemic disorder resulting from
CC       mitochondrial dysfunction associated with mitochondrial depletion
CC       in skeletal muscle and peripheral nerve tissue. The clinical triad
CC       of symptoms consists of sensory ataxic neuropathy, dysarthria, and
CC       ophthalmoparesis. However, the phenotype varies widely, even
CC       within the same family, and can also include myopathy, seizures,
CC       and hearing loss. {ECO:0000269|PubMed:12565911,
CC       ECO:0000269|PubMed:14745080, ECO:0000269|PubMed:15477547,
CC       ECO:0000269|PubMed:15824347, ECO:0000269|PubMed:15917273,
CC       ECO:0000269|PubMed:16080118, ECO:0000269|PubMed:16621917,
CC       ECO:0000269|PubMed:16639411, ECO:0000269|PubMed:16919951}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Mitochondrial DNA depletion syndrome 4A (MTDPS4A)
CC       [MIM:203700]: An autosomal recessive hepatocerebral syndrome due
CC       to mitochondrial dysfunction. The typical course of the disease
CC       includes severe developmental delay, intractable seizures, liver
CC       failure, and death in childhood. Refractory seizures, cortical
CC       blindness, progressive liver dysfunction, and acute liver failure
CC       after exposure to valproic acid are considered diagnostic
CC       features. The neuropathological hallmarks are neuronal loss,
CC       spongiform degeneration, and astrocytosis of the visual cortex.
CC       Liver biopsy results show steatosis, often progressing to
CC       cirrhosis. {ECO:0000269|PubMed:15122711,
CC       ECO:0000269|PubMed:15689359, ECO:0000269|PubMed:15929042,
CC       ECO:0000269|PubMed:16621917, ECO:0000269|PubMed:16639411,
CC       ECO:0000269|PubMed:18828154}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Mitochondrial DNA depletion syndrome 4B (MTDPS4B)
CC       [MIM:613662]: An autosomal recessive progressive multisystem
CC       disorder due to mitochondrial dysfunction. It is clinically
CC       characterized by chronic gastrointestinal dysmotility and pseudo-
CC       obstruction, cachexia, progressive external ophthalmoplegia,
CC       axonal sensory ataxic neuropathy, and muscle weakness.
CC       {ECO:0000269|PubMed:12825077, ECO:0000269|PubMed:19307547}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset
CC       progressive neurodegenerative disorder characterized by the
CC       presence of focal, bilateral lesions in one or more areas of the
CC       central nervous system including the brainstem, thalamus, basal
CC       ganglia, cerebellum and spinal cord. Clinical features depend on
CC       which areas of the central nervous system are involved and include
CC       subacute onset of psychomotor retardation, hypotonia, ataxia,
CC       weakness, vision loss, eye movement abnormalities, seizures, and
CC       dysphagia. {ECO:0000269|PubMed:18828154}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Spinocerebellar ataxia with epilepsy (SCAE) [MIM:607459]:
CC       An autosomal recessive syndrome characterized by headaches and/or
CC       seizures manifesting in childhood or adolescence, cerebellar and
CC       sensory ataxia, dysarthria, and myoclonus manifesting in early
CC       adulthood. Neuropathological findings include spinocerebellar
CC       degeneration associated with cortical neuronal degeneration in
CC       advanced cases. {ECO:0000269|PubMed:26942291}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the DNA polymerase type-A family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/polg/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U60325; AAC50712.1; -; mRNA.
DR   EMBL; X98093; CAA66719.1; -; mRNA.
DR   EMBL; D84103; BAA12223.1; -; mRNA.
DR   EMBL; AF497906; AAM77583.1; -; Genomic_DNA.
DR   EMBL; BC042571; AAH42571.1; -; mRNA.
DR   EMBL; BC050559; AAH50559.1; -; mRNA.
DR   CCDS; CCDS10350.1; -.
DR   PIR; G02750; G02750.
DR   RefSeq; NP_001119603.1; NM_001126131.1.
DR   RefSeq; NP_002684.1; NM_002693.2.
DR   UniGene; Hs.706868; -.
DR   PDB; 3IKM; X-ray; 3.24 A; A/D=70-1239.
DR   PDB; 4ZTU; X-ray; 3.30 A; A=30-1239.
DR   PDB; 4ZTZ; X-ray; 3.44 A; A=30-1239.
DR   PDB; 5C51; X-ray; 3.43 A; A=25-1239.
DR   PDB; 5C52; X-ray; 3.64 A; A=25-1239.
DR   PDB; 5C53; X-ray; 3.57 A; A=25-1239.
DR   PDBsum; 3IKM; -.
DR   PDBsum; 4ZTU; -.
DR   PDBsum; 4ZTZ; -.
DR   PDBsum; 5C51; -.
DR   PDBsum; 5C52; -.
DR   PDBsum; 5C53; -.
DR   ProteinModelPortal; P54098; -.
DR   SMR; P54098; -.
DR   BioGrid; 111424; 15.
DR   IntAct; P54098; 7.
DR   MINT; MINT-4531455; -.
DR   STRING; 9606.ENSP00000268124; -.
DR   BindingDB; P54098; -.
DR   ChEMBL; CHEMBL2732; -.
DR   iPTMnet; P54098; -.
DR   PhosphoSitePlus; P54098; -.
DR   BioMuta; POLG; -.
DR   DMDM; 1706507; -.
DR   EPD; P54098; -.
DR   MaxQB; P54098; -.
DR   PaxDb; P54098; -.
DR   PeptideAtlas; P54098; -.
DR   PRIDE; P54098; -.
DR   Ensembl; ENST00000268124; ENSP00000268124; ENSG00000140521.
DR   Ensembl; ENST00000442287; ENSP00000399851; ENSG00000140521.
DR   GeneID; 5428; -.
DR   KEGG; hsa:5428; -.
DR   UCSC; uc002bnr.5; human.
DR   CTD; 5428; -.
DR   DisGeNET; 5428; -.
DR   GeneCards; POLG; -.
DR   GeneReviews; POLG; -.
DR   HGNC; HGNC:9179; POLG.
DR   HPA; HPA056821; -.
DR   MalaCards; POLG; -.
DR   MIM; 157640; phenotype.
DR   MIM; 174763; gene.
DR   MIM; 203700; phenotype.
DR   MIM; 256000; phenotype.
DR   MIM; 258450; phenotype.
DR   MIM; 607459; phenotype.
DR   MIM; 613662; phenotype.
DR   neXtProt; NX_P54098; -.
DR   OpenTargets; ENSG00000140521; -.
DR   Orphanet; 726; Alpers syndrome.
DR   Orphanet; 254892; Autosomal dominant progressive external ophthalmoplegia.
DR   Orphanet; 254886; Autosomal recessive progressive external ophthalmoplegia.
DR   Orphanet; 298; Mitochondrial neurogastrointestinal encephalomyopathy.
DR   Orphanet; 94125; Recessive mitochondrial ataxia syndrome.
DR   Orphanet; 70595; Sensory ataxic neuropathy - dysarthria - ophthalmoparesis.
DR   Orphanet; 254881; Spinocerebellar ataxia with epilepsy.
DR   PharmGKB; PA33500; -.
DR   eggNOG; KOG3657; Eukaryota.
DR   eggNOG; COG0749; LUCA.
DR   GeneTree; ENSGT00390000000453; -.
DR   HOGENOM; HOG000176668; -.
DR   HOVERGEN; HBG051400; -.
DR   InParanoid; P54098; -.
DR   KO; K02332; -.
DR   OMA; WTPGPSL; -.
DR   OrthoDB; EOG091G028G; -.
DR   PhylomeDB; P54098; -.
DR   ChiTaRS; POLG; human.
DR   GeneWiki; POLG; -.
DR   GenomeRNAi; 5428; -.
DR   PRO; PR:P54098; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000140521; -.
DR   CleanEx; HS_POLG; -.
DR   ExpressionAtlas; P54098; baseline and differential.
DR   Genevisible; P54098; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005760; C:gamma DNA polymerase complex; IEA:Ensembl.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; TAS:ProtInc.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0008408; F:3'-5' exonuclease activity; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IDA:MGI.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006287; P:base-excision repair, gap-filling; IDA:MGI.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0006259; P:DNA metabolic process; TAS:ProtInc.
DR   GO; GO:0006261; P:DNA-dependent DNA replication; TAS:ProtInc.
DR   GO; GO:0006264; P:mitochondrial DNA replication; IBA:GO_Central.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0009416; P:response to light stimulus; IEA:Ensembl.
DR   Gene3D; 2.130.10.10; -; 1.
DR   Gene3D; 3.30.420.10; -; 1.
DR   InterPro; IPR019760; DNA-dir_DNA_pol_A_CS.
DR   InterPro; IPR002297; DNA-dir_DNA_pol_A_mt.
DR   InterPro; IPR001098; DNA-dir_DNA_pol_A_palm_dom.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   PANTHER; PTHR10267; PTHR10267; 1.
DR   Pfam; PF00476; DNA_pol_A; 1.
DR   PIRSF; PIRSF000797; DNA_pol_mt; 1.
DR   PRINTS; PR00867; DNAPOLG.
DR   SMART; SM00482; POLAc; 1.
DR   SUPFAM; SSF53098; SSF53098; 3.
DR   PROSITE; PS00447; DNA_POLYMERASE_A; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disease mutation; DNA replication;
KW   DNA-binding; DNA-directed DNA polymerase; Epilepsy; Leigh syndrome;
KW   Magnesium; Mitochondrion; Mitochondrion nucleoid; Neurodegeneration;
KW   Neuropathy; Nucleotidyltransferase; Polymorphism;
KW   Progressive external ophthalmoplegia; Reference proteome; Transferase.
FT   CHAIN         1   1239       DNA polymerase subunit gamma-1.
FT                                /FTId=PRO_0000101270.
FT   COMPBIAS     43     60       Poly-Gln.
FT   COMPBIAS    535    538       Poly-Glu.
FT   VARIANT       3      3       R -> P (in PEOB1; dbSNP:rs121918045).
FT                                {ECO:0000269|PubMed:11431686,
FT                                ECO:0000269|PubMed:12565911}.
FT                                /FTId=VAR_012153.
FT   VARIANT      18     18       P -> S (in dbSNP:rs3087373).
FT                                /FTId=VAR_014904.
FT   VARIANT      55     55       Q -> QQ. {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_019265.
FT   VARIANT      55     55       Q -> QQQ. {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019266.
FT   VARIANT     193    193       R -> Q (in dbSNP:rs3176162).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_019267.
FT   VARIANT     227    227       R -> W (in PEOB1 and MTDPS4B;
FT                                dbSNP:rs121918056).
FT                                {ECO:0000269|PubMed:12707443,
FT                                ECO:0000269|PubMed:15349879,
FT                                ECO:0000269|PubMed:19307547}.
FT                                /FTId=VAR_023663.
FT   VARIANT     232    232       R -> G (in MTDPS4A).
FT                                {ECO:0000269|PubMed:15689359}.
FT                                /FTId=VAR_058870.
FT   VARIANT     232    232       R -> H (in LS; dbSNP:rs113994093).
FT                                {ECO:0000269|PubMed:18828154}.
FT                                /FTId=VAR_058871.
FT   VARIANT     244    244       L -> P (in MTDPS4A).
FT                                {ECO:0000269|PubMed:15689359}.
FT                                /FTId=VAR_058872.
FT   VARIANT     251    251       T -> I (in PEOB1, MTDPS4A and MTDPS4B;
FT                                dbSNP:rs113994094).
FT                                {ECO:0000269|PubMed:12210792,
FT                                ECO:0000269|PubMed:12707443,
FT                                ECO:0000269|PubMed:12825077,
FT                                ECO:0000269|PubMed:14635118,
FT                                ECO:0000269|PubMed:18828154,
FT                                ECO:0000269|PubMed:26942291}.
FT                                /FTId=VAR_023664.
FT   VARIANT     268    268       G -> A (in PEOB1; sporadic case;
FT                                dbSNP:rs61752784).
FT                                {ECO:0000269|PubMed:14635118}.
FT                                /FTId=VAR_058873.
FT   VARIANT     304    304       L -> R (in PEOB1; also found in SANDO;
FT                                dbSNP:rs121918044).
FT                                {ECO:0000269|PubMed:11431686,
FT                                ECO:0000269|PubMed:12565911,
FT                                ECO:0000269|PubMed:16639411}.
FT                                /FTId=VAR_012154.
FT   VARIANT     304    304       L -> SANDO (in PEOB1).
FT                                /FTId=VAR_058874.
FT   VARIANT     308    308       Q -> H (in PEOB1; sporadic case;
FT                                dbSNP:rs745539599).
FT                                {ECO:0000269|PubMed:16621917}.
FT                                /FTId=VAR_058875.
FT   VARIANT     309    309       R -> L (in PEOB1).
FT                                {ECO:0000269|PubMed:12210792,
FT                                ECO:0000269|PubMed:15349879}.
FT                                /FTId=VAR_023665.
FT   VARIANT     312    312       W -> R (in PEOB1; sporadic case).
FT                                {ECO:0000269|PubMed:12707443,
FT                                ECO:0000269|PubMed:14635118}.
FT                                /FTId=VAR_023666.
FT   VARIANT     324    324       P -> S (in dbSNP:rs2307437).
FT                                /FTId=VAR_014905.
FT   VARIANT     380    380       G -> D (in PEOB1).
FT                                {ECO:0000269|PubMed:16639411}.
FT                                /FTId=VAR_058876.
FT   VARIANT     431    431       G -> V (in PEOB1; sporadic case).
FT                                {ECO:0000269|PubMed:12707443}.
FT                                /FTId=VAR_023667.
FT   VARIANT     463    463       L -> F (in dbSNP:rs150828914).
FT                                {ECO:0000269|PubMed:17420318}.
FT                                /FTId=VAR_058877.
FT   VARIANT     467    467       A -> T (in PEOB1, SANDO, SCAE and
FT                                MTDPS4A; results in clearly decreased
FT                                activity, DNA binding and processivity of
FT                                the polymerase; dbSNP:rs113994095).
FT                                {ECO:0000269|PubMed:11431686,
FT                                ECO:0000269|PubMed:12565911,
FT                                ECO:0000269|PubMed:12707443,
FT                                ECO:0000269|PubMed:14635118,
FT                                ECO:0000269|PubMed:14694057,
FT                                ECO:0000269|PubMed:15122711,
FT                                ECO:0000269|PubMed:15477547,
FT                                ECO:0000269|PubMed:15689359,
FT                                ECO:0000269|PubMed:15824347,
FT                                ECO:0000269|PubMed:15917273,
FT                                ECO:0000269|PubMed:16639411,
FT                                ECO:0000269|PubMed:18828154,
FT                                ECO:0000269|PubMed:26942291}.
FT                                /FTId=VAR_012155.
FT   VARIANT     468    468       N -> D (in PEOB1; dbSNP:rs145843073).
FT                                {ECO:0000269|PubMed:15351195}.
FT                                /FTId=VAR_023668.
FT   VARIANT     497    497       Q -> H (in SANDO and SCAE;
FT                                dbSNP:rs121918052).
FT                                {ECO:0000269|PubMed:15824347,
FT                                ECO:0000269|PubMed:26942291}.
FT                                /FTId=VAR_023669.
FT   VARIANT     511    511       S -> N (in PEOA1; dbSNP:rs121918055).
FT                                {ECO:0000269|PubMed:17420318}.
FT                                /FTId=VAR_058878.
FT   VARIANT     517    517       G -> V (in SANDO; dbSNP:rs61752783).
FT                                {ECO:0000269|PubMed:16621917}.
FT                                /FTId=VAR_058879.
FT   VARIANT     546    546       R -> C (in dbSNP:rs2307447).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014906.
FT   VARIANT     562    562       R -> Q (in PEOB1; sporadic case;
FT                                dbSNP:rs781168350).
FT                                {ECO:0000269|PubMed:14635118}.
FT                                /FTId=VAR_058880.
FT   VARIANT     574    574       R -> W (in PEOB1; sporadic case;
FT                                dbSNP:rs774474723).
FT                                {ECO:0000269|PubMed:16621917}.
FT                                /FTId=VAR_058881.
FT   VARIANT     579    579       R -> W (in PEOB1; dbSNP:rs556925652).
FT                                {ECO:0000269|PubMed:12975295}.
FT                                /FTId=VAR_023670.
FT   VARIANT     587    587       P -> L (in PEOB1, MTDPS4A and MTDPS4B;
FT                                dbSNP:rs113994096).
FT                                {ECO:0000269|PubMed:12825077,
FT                                ECO:0000269|PubMed:12975295,
FT                                ECO:0000269|PubMed:14635118,
FT                                ECO:0000269|PubMed:15349879,
FT                                ECO:0000269|PubMed:15689359,
FT                                ECO:0000269|PubMed:18828154}.
FT                                /FTId=VAR_023671.
FT   VARIANT     603    603       M -> L (in PEOB1).
FT                                {ECO:0000269|PubMed:16401742}.
FT                                /FTId=VAR_058882.
FT   VARIANT     627    627       R -> Q (in SANDO; shows DNA binding
FT                                affinity and processivities similar to
FT                                the controls; dbSNP:rs375305567).
FT                                {ECO:0000269|PubMed:15917273}.
FT                                /FTId=VAR_058883.
FT   VARIANT     627    627       R -> W (in SANDO; sporadic case;
FT                                dbSNP:rs121918046).
FT                                {ECO:0000269|PubMed:12565911}.
FT                                /FTId=VAR_023672.
FT   VARIANT     648    648       P -> R (in PEOB1; sporadic case; also in
FT                                SANDO; dbSNP:rs796052906).
FT                                {ECO:0000269|PubMed:16621917,
FT                                ECO:0000269|PubMed:16919951}.
FT                                /FTId=VAR_058884.
FT   VARIANT     662    662       E -> K (in dbSNP:rs2307450).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014907.
FT   VARIANT     737    737       G -> R (in PEOB1; with absence of
FT                                progressive external ophthalmoplegia;
FT                                dbSNP:rs121918054).
FT                                {ECO:0000269|PubMed:16634032}.
FT                                /FTId=VAR_058885.
FT   VARIANT     748    748       W -> S (in SANDO, SCAE and MTDPS4A;
FT                                dbSNP:rs113994097).
FT                                {ECO:0000269|PubMed:15477547,
FT                                ECO:0000269|PubMed:15824347,
FT                                ECO:0000269|PubMed:15929042,
FT                                ECO:0000269|PubMed:16080118,
FT                                ECO:0000269|PubMed:16639411,
FT                                ECO:0000269|PubMed:18828154}.
FT                                /FTId=VAR_023673.
FT   VARIANT     767    767       A -> D (in MTDPS4A).
FT                                {ECO:0000269|PubMed:16621917}.
FT                                /FTId=VAR_058886.
FT   VARIANT     807    807       R -> C (in SANDO; dbSNP:rs769827124).
FT                                {ECO:0000269|PubMed:16919951}.
FT                                /FTId=VAR_058887.
FT   VARIANT     807    807       R -> P (in PEOB1; sporadic case).
FT                                {ECO:0000269|PubMed:14635118}.
FT                                /FTId=VAR_058888.
FT   VARIANT     831    831       Y -> C (in PEOA1 and MTDPS4A; unknown
FT                                pathological significance;
FT                                dbSNP:rs4154971).
FT                                {ECO:0000269|PubMed:15534189,
FT                                ECO:0000269|PubMed:17846414,
FT                                ECO:0000269|PubMed:18828154}.
FT                                /FTId=VAR_023674.
FT   VARIANT     848    848       G -> S (in PEOB1, MTDPS4A, MTDPS4B and
FT                                LS; dbSNP:rs113994098).
FT                                {ECO:0000269|PubMed:12210792,
FT                                ECO:0000269|PubMed:12872260,
FT                                ECO:0000269|PubMed:15689359,
FT                                ECO:0000269|PubMed:15929042,
FT                                ECO:0000269|PubMed:18828154,
FT                                ECO:0000269|PubMed:19307547}.
FT                                /FTId=VAR_023675.
FT   VARIANT     853    853       R -> W (in PEOB1; with absence of
FT                                progressive external ophthalmoplegia;
FT                                dbSNP:rs121918053).
FT                                {ECO:0000269|PubMed:16401742,
FT                                ECO:0000269|PubMed:16634032}.
FT                                /FTId=VAR_058889.
FT   VARIANT     864    864       N -> S (in MTDPS4B; dbSNP:rs121918050).
FT                                {ECO:0000269|PubMed:12825077}.
FT                                /FTId=VAR_023676.
FT   VARIANT     879    879       Q -> H (in MTDPS4A).
FT                                {ECO:0000269|PubMed:16621917}.
FT                                /FTId=VAR_058890.
FT   VARIANT     885    885       T -> S (in MTDPS4A).
FT                                {ECO:0000269|PubMed:16621917}.
FT                                /FTId=VAR_058891.
FT   VARIANT     889    889       A -> T (in PEOB1; dbSNP:rs763393580).
FT                                {ECO:0000269|PubMed:12975295}.
FT                                /FTId=VAR_023677.
FT   VARIANT     914    914       T -> P (in MTDPS4A; dbSNP:rs139590686).
FT                                {ECO:0000269|PubMed:16621917,
FT                                ECO:0000269|PubMed:16639411,
FT                                ECO:0000269|PubMed:18828154}.
FT                                /FTId=VAR_058892.
FT   VARIANT     923    923       G -> D (in PEOA1).
FT                                {ECO:0000269|PubMed:12210792}.
FT                                /FTId=VAR_023678.
FT   VARIANT     932    932       H -> Y (in SANDO and PEOB1; sporadic
FT                                case; dbSNP:rs121918048).
FT                                {ECO:0000269|PubMed:14635118,
FT                                ECO:0000269|PubMed:14745080}.
FT                                /FTId=VAR_023679.
FT   VARIANT     943    943       R -> H (in PEOA1).
FT                                {ECO:0000269|PubMed:12210792}.
FT                                /FTId=VAR_023680.
FT   VARIANT     953    953       R -> C (in PEOA1; dbSNP:rs11546842).
FT                                {ECO:0000269|PubMed:15351195}.
FT                                /FTId=VAR_023681.
FT   VARIANT     955    955       Y -> C (in PEOA1; can underlie
FT                                parkinsonism; 45-fold decrease in
FT                                apparent binding affinity for the
FT                                incoming nucleoside triphosphate; 2-fold
FT                                less accurate for basepair substitutions
FT                                than wild-type; dbSNP:rs113994099).
FT                                {ECO:0000269|PubMed:11431686,
FT                                ECO:0000269|PubMed:11897778,
FT                                ECO:0000269|PubMed:12210792,
FT                                ECO:0000269|PubMed:12565911,
FT                                ECO:0000269|PubMed:15351195}.
FT                                /FTId=VAR_012156.
FT   VARIANT     957    957       A -> P (in MTDPS4A).
FT                                {ECO:0000269|PubMed:15689359}.
FT                                /FTId=VAR_058893.
FT   VARIANT     957    957       A -> S (in PEOA1; dbSNP:rs121918051).
FT                                {ECO:0000269|PubMed:12210792}.
FT                                /FTId=VAR_023682.
FT   VARIANT    1047   1047       R -> Q (in PEOB1; sporadic case;
FT                                dbSNP:rs768028281).
FT                                {ECO:0000269|PubMed:12707443}.
FT                                /FTId=VAR_023683.
FT   VARIANT    1051   1051       G -> R (in SANDO; dbSNP:rs121918049).
FT                                {ECO:0000269|PubMed:14745080}.
FT                                /FTId=VAR_023684.
FT   VARIANT    1076   1076       G -> V (in PEOB1).
FT                                {ECO:0000269|PubMed:12975295}.
FT                                /FTId=VAR_023685.
FT   VARIANT    1096   1096       R -> C (in PEOB1; sporadic case;
FT                                dbSNP:rs201732356).
FT                                {ECO:0000269|PubMed:12707443}.
FT                                /FTId=VAR_023686.
FT   VARIANT    1096   1096       R -> H (in MTDPS4A; dbSNP:rs368435864).
FT                                {ECO:0000269|PubMed:16621917}.
FT                                /FTId=VAR_058894.
FT   VARIANT    1104   1104       S -> C (in PEOB1; sporadic case).
FT                                {ECO:0000269|PubMed:12707443}.
FT                                /FTId=VAR_023687.
FT   VARIANT    1105   1105       A -> T (in PEOB1; dbSNP:rs753410045).
FT                                {ECO:0000269|PubMed:15351195}.
FT                                /FTId=VAR_023688.
FT   VARIANT    1106   1106       V -> I (in PEOB1).
FT                                {ECO:0000269|PubMed:15349879}.
FT                                /FTId=VAR_023689.
FT   VARIANT    1110   1110       H -> Y (in MTDPS4A).
FT                                {ECO:0000269|PubMed:18828154}.
FT                                /FTId=VAR_058895.
FT   VARIANT    1134   1134       H -> R (in MTDPS4A).
FT                                {ECO:0000269|PubMed:18828154}.
FT                                /FTId=VAR_058896.
FT   VARIANT    1136   1136       E -> K (in MTDPS4A; dbSNP:rs56047213).
FT                                {ECO:0000269|PubMed:18828154}.
FT                                /FTId=VAR_065092.
FT   VARIANT    1142   1142       R -> W (in dbSNP:rs2307442).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014908.
FT   VARIANT    1143   1143       E -> G (in dbSNP:rs2307441).
FT                                {ECO:0000269|PubMed:14635118,
FT                                ECO:0000269|PubMed:15477547,
FT                                ECO:0000269|PubMed:15689359,
FT                                ECO:0000269|PubMed:16080118,
FT                                ECO:0000269|PubMed:16639411,
FT                                ECO:0000269|PubMed:18828154,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014909.
FT   VARIANT    1146   1146       R -> C (in PEOB1; dbSNP:rs2307440).
FT                                {ECO:0000269|PubMed:16401742,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014910.
FT   VARIANT    1176   1176       S -> L (in PEOA1; dbSNP:rs776031396).
FT                                {ECO:0000269|PubMed:12210792,
FT                                ECO:0000269|PubMed:15349879}.
FT                                /FTId=VAR_023690.
FT   VARIANT    1184   1184       D -> N (in PEOB1).
FT                                {ECO:0000269|PubMed:16401742}.
FT                                /FTId=VAR_058897.
FT   VARIANT    1186   1186       D -> H (in PEOA1).
FT                                {ECO:0000269|PubMed:18575922}.
FT                                /FTId=VAR_065119.
FT   VARIANT    1191   1191       K -> N (in MTDPS4A).
FT                                {ECO:0000269|PubMed:16621917}.
FT                                /FTId=VAR_058898.
FT   VARIANT    1236   1236       Q -> H (in dbSNP:rs3087374).
FT                                {ECO:0000269|PubMed:12975295,
FT                                ECO:0000269|PubMed:14635118,
FT                                ECO:0000269|PubMed:15917273,
FT                                ECO:0000269|PubMed:16639411,
FT                                ECO:0000269|PubMed:18828154,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014911.
FT   STRAND       75     77       {ECO:0000244|PDB:3IKM}.
FT   HELIX        83     86       {ECO:0000244|PDB:3IKM}.
FT   HELIX        97    105       {ECO:0000244|PDB:3IKM}.
FT   TURN        106    111       {ECO:0000244|PDB:3IKM}.
FT   STRAND      114    116       {ECO:0000244|PDB:3IKM}.
FT   STRAND      132    134       {ECO:0000244|PDB:5C51}.
FT   HELIX       135    159       {ECO:0000244|PDB:3IKM}.
FT   STRAND      173    178       {ECO:0000244|PDB:4ZTU}.
FT   STRAND      179    181       {ECO:0000244|PDB:3IKM}.
FT   STRAND      184    189       {ECO:0000244|PDB:4ZTU}.
FT   STRAND      192    195       {ECO:0000244|PDB:3IKM}.
FT   STRAND      198    201       {ECO:0000244|PDB:4ZTU}.
FT   HELIX       203    205       {ECO:0000244|PDB:4ZTU}.
FT   STRAND      207    210       {ECO:0000244|PDB:3IKM}.
FT   HELIX       224    227       {ECO:0000244|PDB:3IKM}.
FT   STRAND      235    237       {ECO:0000244|PDB:3IKM}.
FT   STRAND      240    242       {ECO:0000244|PDB:3IKM}.
FT   TURN        243    247       {ECO:0000244|PDB:3IKM}.
FT   HELIX       248    251       {ECO:0000244|PDB:3IKM}.
FT   STRAND      254    256       {ECO:0000244|PDB:3IKM}.
FT   STRAND      260    262       {ECO:0000244|PDB:3IKM}.
FT   STRAND      265    268       {ECO:0000244|PDB:4ZTU}.
FT   STRAND      271    274       {ECO:0000244|PDB:3IKM}.
FT   HELIX       277    279       {ECO:0000244|PDB:3IKM}.
FT   STRAND      282    285       {ECO:0000244|PDB:4ZTU}.
FT   STRAND      290    293       {ECO:0000244|PDB:4ZTU}.
FT   HELIX       296    301       {ECO:0000244|PDB:3IKM}.
FT   HELIX       306    317       {ECO:0000244|PDB:3IKM}.
FT   HELIX       347    349       {ECO:0000244|PDB:4ZTU}.
FT   HELIX       354    360       {ECO:0000244|PDB:3IKM}.
FT   STRAND      373    376       {ECO:0000244|PDB:3IKM}.
FT   TURN        377    380       {ECO:0000244|PDB:3IKM}.
FT   HELIX       385    415       {ECO:0000244|PDB:3IKM}.
FT   HELIX       422    431       {ECO:0000244|PDB:3IKM}.
FT   STRAND      435    438       {ECO:0000244|PDB:4ZTU}.
FT   HELIX       440    473       {ECO:0000244|PDB:3IKM}.
FT   HELIX       478    480       {ECO:0000244|PDB:4ZTU}.
FT   HELIX       483    490       {ECO:0000244|PDB:3IKM}.
FT   STRAND      503    505       {ECO:0000244|PDB:5C51}.
FT   STRAND      519    521       {ECO:0000244|PDB:3IKM}.
FT   STRAND      537    540       {ECO:0000244|PDB:3IKM}.
FT   HELIX       541    558       {ECO:0000244|PDB:3IKM}.
FT   STRAND      559    561       {ECO:0000244|PDB:3IKM}.
FT   STRAND      563    568       {ECO:0000244|PDB:3IKM}.
FT   HELIX       571    575       {ECO:0000244|PDB:4ZTU}.
FT   STRAND      587    589       {ECO:0000244|PDB:3IKM}.
FT   TURN        592    595       {ECO:0000244|PDB:3IKM}.
FT   TURN        597    604       {ECO:0000244|PDB:3IKM}.
FT   STRAND      607    610       {ECO:0000244|PDB:4ZTU}.
FT   STRAND      616    618       {ECO:0000244|PDB:3IKM}.
FT   STRAND      627    629       {ECO:0000244|PDB:3IKM}.
FT   HELIX       636    644       {ECO:0000244|PDB:3IKM}.
FT   HELIX       647    671       {ECO:0000244|PDB:3IKM}.
FT   HELIX       716    721       {ECO:0000244|PDB:3IKM}.
FT   TURN        738    740       {ECO:0000244|PDB:3IKM}.
FT   STRAND      743    745       {ECO:0000244|PDB:4ZTU}.
FT   TURN        755    757       {ECO:0000244|PDB:3IKM}.
FT   HELIX       770    775       {ECO:0000244|PDB:3IKM}.
FT   STRAND      776    778       {ECO:0000244|PDB:3IKM}.
FT   STRAND      784    786       {ECO:0000244|PDB:3IKM}.
FT   HELIX       787    810       {ECO:0000244|PDB:3IKM}.
FT   STRAND      818    821       {ECO:0000244|PDB:3IKM}.
FT   TURN        822    829       {ECO:0000244|PDB:3IKM}.
FT   STRAND      833    835       {ECO:0000244|PDB:3IKM}.
FT   STRAND      837    840       {ECO:0000244|PDB:4ZTU}.
FT   STRAND      845    848       {ECO:0000244|PDB:4ZTU}.
FT   TURN        849    851       {ECO:0000244|PDB:3IKM}.
FT   STRAND      853    855       {ECO:0000244|PDB:4ZTU}.
FT   HELIX       859    861       {ECO:0000244|PDB:3IKM}.
FT   STRAND      867    869       {ECO:0000244|PDB:4ZTU}.
FT   TURN        870    873       {ECO:0000244|PDB:4ZTU}.
FT   HELIX       875    878       {ECO:0000244|PDB:3IKM}.
FT   STRAND      884    890       {ECO:0000244|PDB:3IKM}.
FT   HELIX       894    906       {ECO:0000244|PDB:3IKM}.
FT   STRAND      907    909       {ECO:0000244|PDB:3IKM}.
FT   TURN        914    919       {ECO:0000244|PDB:3IKM}.
FT   TURN        924    926       {ECO:0000244|PDB:3IKM}.
FT   HELIX       929    937       {ECO:0000244|PDB:3IKM}.
FT   HELIX       944    955       {ECO:0000244|PDB:3IKM}.
FT   HELIX       960    969       {ECO:0000244|PDB:3IKM}.
FT   HELIX       974    990       {ECO:0000244|PDB:3IKM}.
FT   STRAND      992    995       {ECO:0000244|PDB:3IKM}.
FT   STRAND      997    999       {ECO:0000244|PDB:3IKM}.
FT   HELIX      1001   1009       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1010   1013       {ECO:0000244|PDB:3IKM}.
FT   HELIX      1027   1030       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1033   1035       {ECO:0000244|PDB:3IKM}.
FT   HELIX      1037   1040       {ECO:0000244|PDB:3IKM}.
FT   TURN       1041   1046       {ECO:0000244|PDB:3IKM}.
FT   HELIX      1047   1058       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1061   1065       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1068   1070       {ECO:0000244|PDB:3IKM}.
FT   TURN       1073   1075       {ECO:0000244|PDB:5C51}.
FT   TURN       1081   1083       {ECO:0000244|PDB:4ZTU}.
FT   HELIX      1093   1121       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1122   1124       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1130   1133       {ECO:0000244|PDB:4ZTU}.
FT   STRAND     1136   1143       {ECO:0000244|PDB:3IKM}.
FT   HELIX      1146   1168       {ECO:0000244|PDB:3IKM}.
FT   HELIX      1175   1178       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1184   1188       {ECO:0000244|PDB:3IKM}.
FT   HELIX      1193   1195       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1200   1203       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1207   1209       {ECO:0000244|PDB:3IKM}.
FT   HELIX      1220   1227       {ECO:0000244|PDB:3IKM}.
FT   STRAND     1232   1235       {ECO:0000244|PDB:3IKM}.
SQ   SEQUENCE   1239 AA;  139562 MW;  2D9ECCD75AD6E01E CRC64;
     MSRLLWRKVA GATVGPGPVP APGRWVSSSV PASDPSDGQR RRQQQQQQQQ QQQQQPQQPQ
     VLSSEGGQLR HNPLDIQMLS RGLHEQIFGQ GGEMPGEAAV RRSVEHLQKH GLWGQPAVPL
     PDVELRLPPL YGDNLDQHFR LLAQKQSLPY LEAANLLLQA QLPPKPPAWA WAEGWTRYGP
     EGEAVPVAIP EERALVFDVE VCLAEGTCPT LAVAISPSAW YSWCSQRLVE ERYSWTSQLS
     PADLIPLEVP TGASSPTQRD WQEQLVVGHN VSFDRAHIRE QYLIQGSRMR FLDTMSMHMA
     ISGLSSFQRS LWIAAKQGKH KVQPPTKQGQ KSQRKARRGP AISSWDWLDI SSVNSLAEVH
     RLYVGGPPLE KEPRELFVKG TMKDIRENFQ DLMQYCAQDV WATHEVFQQQ LPLFLERCPH
     PVTLAGMLEM GVSYLPVNQN WERYLAEAQG TYEELQREMK KSLMDLANDA CQLLSGERYK
     EDPWLWDLEW DLQEFKQKKA KKVKKEPATA SKLPIEGAGA PGDPMDQEDL GPCSEEEEFQ
     QDVMARACLQ KLKGTTELLP KRPQHLPGHP GWYRKLCPRL DDPAWTPGPS LLSLQMRVTP
     KLMALTWDGF PLHYSERHGW GYLVPGRRDN LAKLPTGTTL ESAGVVCPYR AIESLYRKHC
     LEQGKQQLMP QEAGLAEEFL LTDNSAIWQT VEELDYLEVE AEAKMENLRA AVPGQPLALT
     ARGGPKDTQP SYHHGNGPYN DVDIPGCWFF KLPHKDGNSC NVGSPFAKDF LPKMEDGTLQ
     AGPGGASGPR ALEINKMISF WRNAHKRISS QMVVWLPRSA LPRAVIRHPD YDEEGLYGAI
     LPQVVTAGTI TRRAVEPTWL TASNARPDRV GSELKAMVQA PPGYTLVGAD VDSQELWIAA
     VLGDAHFAGM HGCTAFGWMT LQGRKSRGTD LHSKTATTVG ISREHAKIFN YGRIYGAGQP
     FAERLLMQFN HRLTQQEAAE KAQQMYAATK GLRWYRLSDE GEWLVRELNL PVDRTEGGWI
     SLQDLRKVQR ETARKSQWKK WEVVAERAWK GGTESEMFNK LESIATSDIP RTPVLGCCIS
     RALEPSAVQE EFMTSRVNWV VQSSAVDYLH LMLVAMKWLF EEFAIDGRFC ISIHDEVRYL
     VREEDRYRAA LALQITNLLT RCMFAYKLGL NDLPQSVAFF SAVDIDRCLR KEVTMDCKTP
     SNPTGMERRY GIPQGEALDI YQIIELTKGS LEKRSQPGP
//
